AMPH

#2181
Amphastar Pharmaceuticals, Inc. - Common Stock
18.8 5 USD
+9666.84%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
18.85
18.85
Range Annuel
0.18
29.52
Changement quotidien
+9666.84%
Changement Mensuel
-12.85%
Evolution sur 6 mois
-31.30%
Changement Annuel
-22.68%
Clôture Précédente
0.1 9
Open
18.8 5
Low
18.8 5
High
18.8 5
Volume
93
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 831.15 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
13.19
ratio cours/chiffre d'affaires
1.79

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Nouvelles